280 related articles for article (PubMed ID: 36851789)
1. SARS-CoV-2 Vaccine-Induced T-Cell Response after Three Doses in People Living with HIV on Antiretroviral Therapy Compared to Seronegative Controls (CTN 328 COVAXHIV Study).
Alexandrova Y; Yero A; Mboumba Bouassa RS; Comeau E; Samarani S; Brumme ZL; Hull M; Crawley AM; Langlois MA; Angel JB; Cooper CL; Needham J; Lee T; Singer J; Anis AH; Costiniuk CT; Jenabian MA
Viruses; 2023 Feb; 15(2):. PubMed ID: 36851789
[TBL] [Abstract][Full Text] [Related]
2. T-Cell Responses to COVID-19 Vaccines and Breakthrough Infection in People Living with HIV Receiving Antiretroviral Therapy.
Datwani S; Kalikawe R; Waterworth R; Mwimanzi FM; Liang R; Sang Y; Lapointe HR; Cheung PK; Omondi FH; Duncan MC; Barad E; Speckmaier S; Moran-Garcia N; DeMarco ML; Hedgcock M; Costiniuk CT; Hull M; Harris M; Romney MG; Montaner JSG; Brumme ZL; Brockman MA
Viruses; 2024 Apr; 16(5):. PubMed ID: 38793543
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort study.
Hensley KS; Jongkees MJ; Geers D; GeurtsvanKessel CH; Mueller YM; Dalm VASH; Papageorgiou G; Steggink H; Gorska A; Bogers S; den Hollander JG; Bierman WFW; Gelinck LBS; Schippers EF; Ammerlaan HSM; van der Valk M; van Vonderen MGA; Delsing CE; Gisolf EH; Bruns AHW; Lauw FN; Berrevoets MAH; Sigaloff KCE; Soetekouw R; Branger J; de Mast Q; Lammers AJJ; Lowe SH; de Vries RD; Katsikis PD; Rijnders BJA; Brinkman K; Roukens AHE; Rokx C
PLoS Med; 2022 Oct; 19(10):e1003979. PubMed ID: 36301821
[TBL] [Abstract][Full Text] [Related]
4. Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte Count.
Antinori A; Cicalini S; Meschi S; Bordoni V; Lorenzini P; Vergori A; Lanini S; De Pascale L; Matusali G; Mariotti D; Cozzi Lepri A; Gallì P; Pinnetti C; Gagliardini R; Mazzotta V; Mastrorosa I; Grisetti S; Colavita F; Cimini E; Grilli E; Bellagamba R; Lapa D; Sacchi A; Marani A; Cerini C; Candela C; Fusto M; Puro V; Castilletti C; Agrati C; Girardi E; Vaia F;
Clin Infect Dis; 2022 Aug; 75(1):e552-e563. PubMed ID: 35366316
[TBL] [Abstract][Full Text] [Related]
5. Inactivated SARS-CoV-2 vaccines elicit immunogenicity and T-cell responses in people living with HIV.
Lv Z; Li Q; Feng Z; Zheng X; NaYin ; Yang H; Gu Q; Ying S; Qi Y; Li X; Wu R; Wu Z; Yu X; Zou N; Qin D; Wan C
Int Immunopharmacol; 2022 Jan; 102():108383. PubMed ID: 34824035
[TBL] [Abstract][Full Text] [Related]
6. A tale of two conditions: when people living with HIV meet three doses of inactivated COVID-19 vaccines.
Tan Y; Zou S; Ming F; Wu S; Guo W; Wu M; Tang W; Liang K
Front Immunol; 2023; 14():1174379. PubMed ID: 37404815
[TBL] [Abstract][Full Text] [Related]
7. Humoral and cell-mediated immune responses in HIV-vertically infected young patients after three doses of the BNT162b2 mRNA SARS-CoV-2 vaccine.
Vanetti C; Stracuzzi M; Crivellaro E; Ciciliano F; Garziano M; Fenizia C; Biasin M; Rubinacci V; Amendola A; Tanzi E; Zuccotti GV; Clerici M; Giacomet V; Trabattoni D
Front Immunol; 2023; 14():1301766. PubMed ID: 38250079
[TBL] [Abstract][Full Text] [Related]
8. Relatively preserved functional immune capacity with standard COVID-19 vaccine regimen in people living with HIV.
Hung CY; Hsiao SH; Huang CG; Chang CS; Chen GY; Huang YL; Dutta A; Huang CT
Front Immunol; 2023; 14():1204314. PubMed ID: 37731482
[TBL] [Abstract][Full Text] [Related]
9. Weak SARS-CoV-2-specific responses of TIGIT-expressing CD8 + T cells in people living with HIV after a third dose of a SARS-CoV-2 inactivated vaccine.
Jin J; Wang X; Li Y; Yang X; Wang H; Han X; Sun J; Ma Z; Duan J; Zhang G; Huang T; Zhang T; Wu H; Zhang X; Su B
Chin Med J (Engl); 2023 Dec; 136(24):2938-2947. PubMed ID: 37963586
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and safety of inactivated SARS-CoV-2 vaccines in people living with HIV: A longitudinal cohort study.
Li J; Nie L; Guo C; Deng Y; Guo Q; Pang C; Xin R; Li J; Lu H; Huang C
J Med Virol; 2023 Dec; 95(12):e29334. PubMed ID: 38140842
[TBL] [Abstract][Full Text] [Related]
11. Low pre-existing endemic human coronavirus (HCoV-NL63)-specific T cell frequencies are associated with impaired SARS-CoV-2-specific T cell responses in people living with HIV.
Ng'uni TL; Musale V; Nkosi T; Mandolo J; Mvula M; Michelo C; Karim F; Moosa MYS; Khan K; Jambo KC; Hanekom W; Sigal A; Kilembe W; Ndhlovu ZM
Front Immunol; 2023; 14():1291048. PubMed ID: 38343437
[TBL] [Abstract][Full Text] [Related]
12. Humoral and Cellular Immune Response Elicited by Two Doses of mRNA BNT162b2 Vaccine Against SARS-CoV-2 in People Living with HIV.
Vanetti C; Milazzo L; Ardizzone F; Oreni L; Cappelletti G; Trabattoni D; Biasin M
AIDS Res Hum Retroviruses; 2023 Sep; 39(9):495-499. PubMed ID: 37031355
[TBL] [Abstract][Full Text] [Related]
13. Dynamics of CD4
Zhang W; Liu S; Miao L; Fu A; Bao J; Zheng L; Li E; Yu J; Wang Y
Infect Drug Resist; 2023; 16():2695-2707. PubMed ID: 37168513
[TBL] [Abstract][Full Text] [Related]
14. Cluster Analysis Identifies Distinct Patterns of T-Cell and Humoral Immune Responses Evolution Following a Third Dose of SARS-CoV-2 Vaccine in People Living with HIV.
El Moussaoui M; Desmecht S; Lambert N; Maes N; Braghini J; Marechal N; Quintana C; Briquet K; Gofflot S; Toussaint F; Hayette MP; Vermeersch P; Lutteri L; Grégoire C; Beguin Y; Rahmouni S; Moutschen M; Desmecht D; Darcis G
Viruses; 2023 Jun; 15(7):. PubMed ID: 37515123
[TBL] [Abstract][Full Text] [Related]
15. Comparing Immune Responses to Inactivated Vaccines against SARS-CoV-2 between People Living with HIV and HIV-Negative Individuals: A Cross-Sectional Study in China.
Huang X; Yan Y; Su B; Xiao D; Yu M; Jin X; Duan J; Zhang X; Zheng S; Fang Y; Zhang T; Tang W; Wang L; Wang Z; Xu J
Viruses; 2022 Jan; 14(2):. PubMed ID: 35215870
[TBL] [Abstract][Full Text] [Related]
16. CTN 328: immunogenicity outcomes in people living with HIV in Canada following vaccination for COVID-19 (HIV-COV): protocol for an observational cohort study.
Costiniuk CT; Singer J; Langlois MA; Kulic I; Needham J; Burchell A; Jenabian MA; Walmsley S; Ostrowski M; Kovacs C; Tan D; Harris M; Hull M; Brumme Z; Brockman M; Margolese S; Mandarino E; Angel JB; Routy JP; Anis AH; Cooper C
BMJ Open; 2021 Dec; 11(12):e054208. PubMed ID: 34916326
[TBL] [Abstract][Full Text] [Related]
17. Impaired Functional T-Cell Response to SARS-CoV-2 After Two Doses of BNT162b2 mRNA Vaccine in Older People.
Demaret J; Corroyer-Simovic B; Alidjinou EK; Goffard A; Trauet J; Miczek S; Vuotto F; Dendooven A; Huvent-Grelle D; Podvin J; Dreuil D; Faure K; Deplanque D; Bocket L; Duhamel A; Labreuche J; Sobaszek A; Hisbergues M; Puisieux F; Labalette M; Lefèvre G
Front Immunol; 2021; 12():778679. PubMed ID: 34868051
[TBL] [Abstract][Full Text] [Related]
18. Effect of SARS-CoV-2 Breakthrough Infection on HIV Reservoirs and T-Cell Immune Recovery in 3-Dose Vaccinated People Living with HIV.
Qu MM; Song B; Yang BP; Wang Z; Yu M; Zhang Y; Zhang C; Song JW; Fan X; Xu R; Zhang JY; Zhou CB; Du F; Wang FS; Huang HH; Jiao YM
Viruses; 2023 Dec; 15(12):. PubMed ID: 38140668
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people living with HIV.
Ao L; Lu T; Cao Y; Chen Z; Wang Y; Li Z; Ren X; Xu P; Peng M; Chen M; Zhang G; Xiang D; Cai D; Hu P; Shi X; Zhang D; Ren H
Emerg Microbes Infect; 2022 Dec; 11(1):1126-1134. PubMed ID: 35369854
[TBL] [Abstract][Full Text] [Related]
20. Neutralizing activity and T-cell response after bivalent fifth dose of messenger RNA vaccine in people living with HIV.
Vergori A; Matusali G; Lepri AC; Cimini E; Fusto M; Colavita F; Gagliardini R; Notari S; Mazzotta V; Mariotti D; Cicalini S; Girardi E; Vaia F; Maggi F; Antinori A;
Int J Infect Dis; 2023 Sep; 134():195-199. PubMed ID: 37343783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
